Results 291 to 300 of about 152,178 (350)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Nature Medicine, 2022
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial.
Anna Sophie Berghoff, Maximilian Marhold, Angelika M Starzer   +2 more
exaly   +2 more sources

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nature Medicine, 2021
The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established.
Ken Kato, Yoshito Komatsu, Satoshi Yuki
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Journal of Clinical Oncology, 2023
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ...
C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, M. Press   +12 more
semanticscholar   +1 more source

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Journal of Clinical Oncology, 2020
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib.
Nancy U Lin, Virginia F Borges, Carey K Anders   +2 more
exaly   +2 more sources

Trastuzumab

BioDrugs, 1999
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours. The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
C M, Perry, L R, Wiseman
openaire   +2 more sources

MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases

Science Translational Medicine, 2021
Description MRgFUS is a safe, noninvasive method to deliver spatially targeted monoclonal antibody across the BBB in patients with brain tumors. Focusing on delivery Drug delivery to the brain is hampered by the presence of the blood-brain barrier (BBB).
Y. Meng, R. Reilly, R. Pezo, M. Trudeau, A. Sahgal, Amit Singnurkar, J. Perry, S. Myrehaug, Christopher B. Pople, B. Davidson, Maheleth Llinas, Chinthaka Hyen, Yuexi Huang, C. Hamani, S. Suppiah, K. Hynynen, N. Lipsman   +16 more
semanticscholar   +1 more source

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Cancer Cell, 2004
Keng-Hsueh Lan, Ming Tan, Gabriel N Hortobagyi   +2 more
exaly   +2 more sources

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Journal of Clinical Oncology, 2022
PURPOSE High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable ...
R. Hofheinz, K. Merx, G. Haag, C. Springfeld, T. Ettrich, K. Borchert, A. Kretzschmar, C. Teschendorf, G. Siegler, M. Ebert, E. Goekkurt, R. Mahlberg, N. Homann, D. Pink, W. Bechstein, P. Reichardt, H. Flach, T. Gaiser, A. Battmann, F. Oduncu, M. Loose, D. Sookthai, C. Pauligk, Thorsten O. Göetze, S. Al-Batran   +24 more
semanticscholar   +1 more source

A novel circular RNA confers trastuzumab resistance in human epidermal growth factor receptor 2‐positive breast cancer through regulating ferroptosis

Environmental Toxicology, 2022
HER2‐positive breast cancer is an aggressive subtype of breast cancer, characterized by high malignancy and poor prognosis. Trastuzumab, the first HER2‐targeted monoclonal antibody therapy, has a crucial role in a curative setting in HER2‐positive breast
Shengting Wang, Yufang Wang, Qian Li, Xiaoming Li, Xinghua Feng   +4 more
semanticscholar   +1 more source

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

New England Journal of Medicine
BACKGROUND Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3,
C. E. Geyer, M. Untch, Chiun-Sheng Huang, Max S Mano, E. Mamounas, N. Wolmark, Priya Rastogi, A. Schneeweiss, Andres Redondo, Hans H Fischer, V. D’hondt, Alison K. Conlin, Valentina Guarneri, Irene L. Wapnir, C. Jackisch, C. Arce-Salinas, P. Fasching, M. DiGiovanna, John P Crown, P. Wuelfing, Z. Shao, Elena Rota Caremoli, Hervé R Bonnefoi, Bryan T. Hennessy, L. Stamatović, Hugo Castro-Salguero, A. Brufsky, A. Knott, Asna Siddiqui, C. Lambertini, T. Boulet, B. Nyawira, E. Restuccia, S. Loibl   +33 more
semanticscholar   +1 more source